10-Q: Aquestive Reports Wider Losses Amid Revenue Decline

Aquestive Therapeutics, Inc. reported a significant increase in net loss and a substantial decline in revenue for the second quarter and first half of 2025, primarily due to one-time revenue recognition in the prior year and the halted U.S. market access for Libervant, while its Anaphylm NDA was accepted by the FDA with a January 2026 PDUFA date.

Summary

• Net loss for the three months ended June 30, 2025, increased to $13.548 million from $2.745 million in the prior year period.
• Net loss for the six months ended June 30, 2025, widened to $36.478 million from $15.573 million in the prior year period.
• Total revenues decreased by 50% to $10.003 million for the three months ended June 30, 2025, compared to $20.099 million in the same period last year.
• Total revenues decreased by 42% to $18.723 million for the six months ended June 30, 2025, compared to $32.152 million in the same period last year.
• The decrease in revenue was primarily driven by a 93% decline in license and royalty revenue for the three-month period and 87% for the six-month period, due to one-time recognition of deferred revenues totaling $10.317 million in the prior year from Haisco and MTPA contract terminations.
• Proprietary product revenue (Libervant) decreased by $797 thousand for the three months and $478 thousand for the six months due to the withdrawal of U.S. market access in April 2025.
• Selling, general and administrative expenses increased by 44% to $31.777 million for the six months ended June 30, 2025, largely due to a $4.310 million Anaphylm PDUFA fee and $4.170 million in higher commercial spending.
• Cash and cash equivalents stood at $60.536 million as of June 30, 2025, down from $71.546 million at December 31, 2024.
• Net cash used for operating activities increased to $31.314 million for the six months ended June 30, 2025, compared to $17.390 million in the prior year.
• The company's accumulated deficit reached $399.692 million as of June 30, 2025.
• Anaphylm (epinephrine) Sublingual Film's New Drug Application (NDA) was accepted by the FDA on June 16, 2025, with a PDUFA target action date of January 31, 2026.
• The company plans to initiate a product launch of Anaphylm in the first quarter of 2026, if approved.
• U.S. market access for Libervant (diazepam) Buccal Film for ARS patients aged two to five years was vacated by a U.S. District Court ruling on February 14, 2025, leading the FDA to convert its approval to 'tentative approval' and the company to cease marketing activities.
• Aquestive earned a $500 thousand milestone payment in Q2 2025 related to the sale of Emylif in the EU.
• The company continues to be the exclusive manufacturer and supplier for Suboxone, which retains approximately 26% film market share.
• The remaining authorized balance of the At-The-Market (ATM) facility was $78.000 million as of June 30, 2025, with $21.271 million net proceeds generated in the first half of 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significantly increased net losses, substantial revenue decline, and the major setback with Libervant's U.S. market access being vacated by a court ruling. While Anaphylm's NDA acceptance is a positive development, the overall financial performance and ongoing litigation risks outweigh this progress, indicating a challenging financial position and continued reliance on external funding.

Positives

• Anaphylm's NDA was accepted by the FDA on June 16, 2025, with a PDUFA target action date of January 31, 2026, indicating significant progress towards potential market approval.
• Positive topline data from Anaphylm's pivotal clinical study demonstrated PK biocomparability to epinephrine auto-injectors and met secondary endpoints for PK sustainability, safety, and tolerability.
• Anaphylm's self-administration PK study showed a median time to maximum concentration (Tmax) of 15 minutes, significantly faster than the 50 minutes for IM injection, highlighting a potential patient benefit.
• The OASIS study for Anaphylm showed rapid symptom resolution (median 12 minutes) and consistent PK/PD profiles even during allergen-induced oral physiological changes.
• The pediatric study for Anaphylm (ages 7-17) yielded positive topline data, with PK results consistent with adult studies and a favorable safety profile.
• Aquestive received positive pre-NDA written response feedback from the FDA, indicating no additional adult clinical trials would be necessary for the Anaphylm NDA submission and agreement on planned content and format.
• A $500 thousand milestone payment was earned in Q2 2025 from Zambon for the sale of Emylif in the EU, demonstrating continued revenue from licensed products.
• The company successfully utilized its ATM facility, generating $21.271 million in net proceeds during the first half of 2025, providing near-term liquidity.

Negatives

• Net loss significantly increased to $13.548 million for Q2 2025 and $36.478 million for H1 2025, compared to $2.745 million and $15.573 million in the respective prior year periods.
• Total revenues decreased by 50% for Q2 2025 and 42% for H1 2025, primarily due to the absence of one-time deferred revenue recognition from Haisco and MTPA contract terminations that occurred in the prior year.
• U.S. market access for Libervant for ARS patients aged two to five years was vacated by a U.S. District Court ruling on February 14, 2025, leading to the cessation of marketing activities and conversion to 'tentative approval'.
• The company's accumulated deficit grew to $399.692 million as of June 30, 2025, reflecting a history of net losses.
• Net cash used for operating activities increased by $13.924 million for the six months ended June 30, 2025, indicating higher cash burn.
• Suboxone branded products' film market share has eroded to approximately 26% due to generic competition, impacting a substantial part of current operating revenue.
• The company is unlikely to receive up to $75.000 million in additional contingent payments from the KYNMOBI Monetization Agreement due to Sunovion's voluntary withdrawal of KYNMOBI from U.S. and Canadian markets.
• Selling, general and administrative expenses increased significantly, partly due to the Anaphylm PDUFA fee and higher commercial spending, contributing to increased losses.

Risks

• The company has a history of net losses and accumulated deficits, requiring continued external financing until profitability is achieved.
• The U.S. District Court's ruling vacating Libervant's FDA approval and the ongoing appeal create significant uncertainty regarding future U.S. market access for Libervant for any age group.
• The company faces substantial litigation risks, including product liability lawsuits related to Suboxone, and the ongoing California litigation with Neurelis.
• Reliance on a single major customer, Indivior, for a substantial portion of current operating revenue, with an expected general decline in Suboxone revenue.
• The ability to raise additional capital through debt or equity markets, including the ATM facility, is not assured and could lead to further shareholder dilution or increased repayment obligations.
• Potential delays or failure to receive FDA approval for product candidates like Anaphylm and AQST-108, or the requirement for additional clinical studies.
• Risk of insufficient manufacturing capabilities to support demand for product candidates if approved, or for licensed products.
• Eroding market share for Suboxone due to generic competition poses a risk to current operating revenue.
• The company faces risks related to intellectual property rights and infringement claims, including ongoing patent infringement lawsuits.
• Changes in laws or regulations, including potential tariffs on pharmaceutical imports, could adversely affect operating costs and financial condition.
• The company has substantial ongoing interest payments and principal repayments for its 13.5% Notes starting in June 2026, and royalty obligation payments projected through 2034.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances product candidates through development and clinical trials, ultimately seeking regulatory approval. A product launch for Anaphylm is planned for the first quarter of 2026, if approved by the FDA. The company also plans to open an IND for AQST-108 in the fourth quarter of 2025 and initiate its Phase 2a clinical trial in the first half of 2026. The company will need to raise significant funding to support Anaphylm's commercialization efforts and expects to be dependent on external financing to achieve its operating plan until profitability is reached.

Management Comments

• Management expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances product candidates through all stages of development and clinical trials, ultimately seeking regulatory approval.
• Management believes the company's ongoing business, existing cash and cash equivalents, expense management activities, and access to equity capital markets provide near-term liquidity for at least the next twelve months.
• Management has updated the projected years of payments for Royalty Right Agreements to 2034 and the effective interest rate by 0.56% as of December 31, 2024.
• Management expects to continue to manage business costs to appropriately reflect the anticipated general decline in Suboxone revenue and other external resources or factors affecting the business.
• Management plans to continue to focus on the core drivers of value for stockholders, including continued investments in ongoing product development activities in support of Anaphylm and AQST-108.

Industry Context

The company operates in the specialty pharmaceutical sector, focusing on innovative drug delivery technologies like PharmFilm for complex molecules. Its pipeline addresses significant market opportunities such as severe allergic reactions (anaphylaxis) and epilepsy. The progress of Anaphylm positions the company to potentially introduce the first non-device based, orally delivered epinephrine product, a significant innovation in a market currently dominated by auto-injectors and recently, nasal sprays. The setback with Libervant highlights the competitive and regulatory challenges within the orphan drug space, particularly concerning market exclusivity. The declining market share of Suboxone due to generic competition reflects a broader industry trend where established branded drugs face significant pressure upon patent expiration.

Comparison to Industry Standards

• Anaphylm's clinical results showing PK biocomparability to auto-injectors like EpiPen and Auvi-Q, and a faster median Tmax (15 minutes vs. 50 minutes for IM injection), suggest a potentially superior patient experience compared to existing standards of care for anaphylaxis.
• The vacating of Libervant's FDA approval due to a legal challenge regarding Orphan Drug Exclusivity (ODE) for a competitor (Valtoco) highlights the complex and often litigious nature of market exclusivity in the rare disease space, a common challenge for companies developing treatments for conditions like Lennox-Gastaut syndrome.
• The company's reliance on its ATM facility and other equity offerings for funding is a common strategy for pre-revenue or early-commercial-stage biotech companies, but the significant accumulated deficit and increased cash burn indicate a higher capital need compared to more established, profitable pharmaceutical firms.
• The erosion of Suboxone's market share to generics is a typical lifecycle event for branded pharmaceuticals, underscoring the importance of pipeline development for long-term sustainability, similar to how other companies manage mature product portfolios.

Legal Proceedings

• **California Litigation (Neurelis, Inc. v. Aquestive Therapeutics, Inc.)**: Neurelis alleges unfair competition, defamation, and trade libel. The trial is scheduled for January 5, 2026. The company cannot determine the ultimate outcome or estimate potential loss.
• **Neurelis FDA Lawsuit (Neurelis v. Califf, et al.)**: Neurelis challenged the FDA's approval of Libervant for ARS patients aged two to five years. On February 14, 2025, the U.S. District Court ruled in favor of Neurelis, vacating Libervant's approval. The FDA is appealing this ruling. The company has ceased marketing activities for Libervant in the U.S. and cannot predict the ultimate outcome or whether U.S. market access will be granted before the Orphan Drug Exclusivity expiration.
• **Suboxone Product Liability Litigation**: The company is a defendant in a Multidistrict Litigation (MDL) in Ohio, a state court case in New Jersey, and three proposed class action lawsuits in Canada. Plaintiffs allege dental injuries from Suboxone. Indivior has agreed to defend the company in the U.S. MDL. The company cannot determine the ultimate outcome or estimate potential loss.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential future equity financings and continued operating losses. The vacating of Libervant's approval and ongoing litigation create uncertainty regarding future revenue streams and stock performance. Anaphylm's progress offers potential upside, but its success is critical.
• **Employees**: The company's focus on expense management and potential future reductions in staff or R&D programs could impact employment stability, although continued investment in Anaphylm and AQST-108 development suggests stability in those areas.
• **Customers (Licensees)**: Indivior, Hypera, Assertio, and Zambon continue to be key partners for manufacturing and commercialization. The decline in Suboxone's market share could affect Indivior's demand, while the Libervant setback impacts Pharmanovia's licensed territory outside the U.S. The termination of Haisco and MTPA agreements indicates a shift in licensing relationships.
• **Creditors (Note Holders)**: The company has substantial debt obligations (13.5% Notes) with principal payments starting in June 2026 and royalty obligations. The company's ability to meet these obligations depends on its operating performance and access to capital, posing a risk to creditors.
• **Patients**: The progress of Anaphylm offers hope for a novel, non-invasive treatment for anaphylaxis. The halted U.S. market access for Libervant means patients aged two to five years will not have access to this orally administered rescue therapy in the U.S. for the foreseeable future, impacting patient care options.

Next Steps

• Initiate a product launch of Anaphylm in the first quarter of 2026, if approved by the FDA.
• Continue preparing for a potential advisory committee meeting for Anaphylm, if required by the FDA.
• Pursue regulatory strategies for Anaphylm outside the United States, including a planned meeting with Health Canada and submission of a Marketing Authorization Application to EMA.
• Open an Investigational New Drug (IND) application for AQST-108 in the fourth quarter of 2025.
• Initiate the Phase 2a clinical trial for AQST-108 in the first half of 2026.
• Continue communicating with the FDA on a path forward for approval of Libervant for ARS patients aged between two and five years, potentially based on clinical superiority.
• The FDA is appealing the District Court's ruling regarding Libervant's approval.
• File for FDA approval for use of Libervant for ARS patients aged between 6 and 11 years prior to the expiration of the Orphan Drug Exclusivity for Valtoco.
• Continue to manage business costs to appropriately reflect anticipated general decline in Suboxone revenue.
• Continue to defend against ongoing legal proceedings, including the California Litigation (trial scheduled January 5, 2026) and Suboxone product liability litigation.

Key Dates

Recommendation

The company presents a mixed bag of significant challenges and promising developments. The substantial increase in net losses, significant revenue decline (even accounting for one-time prior year items), and the critical setback with Libervant's U.S. market access being vacated by a court ruling are major concerns. These issues highlight the company's precarious financial position and continued heavy reliance on external capital. However, the positive progress of Anaphylm, including its NDA acceptance by the FDA with a PDUFA date and strong clinical data, represents a significant potential value driver. The future of the company hinges heavily on Anaphylm's approval and successful commercialization. Given the high risk associated with the current financial state and legal challenges, but also the substantial upside potential of Anaphylm, a 'hold' recommendation is appropriate. Investors should monitor Anaphylm's regulatory progress closely and assess the company's ability to secure necessary funding and navigate its legal landscape before making further investment decisions.

Keywords

Pharmaceuticals, Drug Development, SEC Filing, 10-Q, Anaphylm, Epinephrine, Sublingual Film, Libervant, Diazepam, Seizure Clusters, Orphan Drug Exclusivity, AQST-108, Alopecia Areata, Suboxone, Opioid Dependence, PharmFilm, Clinical Trials, FDA Approval, Biotechnology, Specialty Pharma